Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer - Current status and future outlooks.

Triple-negative breast cancer (TNBC) remains one of the most aggressive and therapeutically challenging subtypes of breast cancer, largely due to its lack of hormone receptors and (human epidermal growth factor receptor 2) HER2 expression. Recent advances have highlighted the signal transducer and activator of transcription 3 (STAT3) as a critical oncogenic driver in TNBC pathogenesis and immune evasion, making it a promising target for immunotherapeutic intervention. This review explores the current landscape of STAT3-targeted therapies, discussing the detailed examination of upstream, downstream, and direct inhibitors of STAT3 in cancer management, emphasizing their mechanisms of action and preclinical/clinical progress.